Adverum Biotechnologies, Inc. Common Stock
Symbol: ADVM (NASDAQ)
Company Description:
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $4.18
- Yesterday High: $4.38
- Yesterday Low: $4.15
- Yesterday Volume: 107.52K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: Adverum Biotechnologies, Inc. Common Stock
- Website: https://www.adverum.com
- Listed Date: 2014-07-31
- Location: REDWOOD CITY, CA
- Market Status: Active
- CIK Number: 0001501756
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $93.80M
- Round Lot: 100
- Outstanding Shares: 20.98M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-22 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-05 | SCHEDULE 13G/A | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-20 | 4 | View |
